Supplementary Figure S3 from A Multifunctional Chimeric Chaperone Serves As a Novel Immune Modulator Inducing Therapeutic Antitumor Immunity

Xiaofei Yu,Chunqing Guo,Huanfa Yi,Jie Qian,Paul B. Fisher,John R. Subjeck,Xiang-Yang Wang

DOI: https://doi.org/10.1158/0008-5472.22399034

2023-01-01

Abstract:Supplementary Figure S3 PDF file - 99K, Effects of Ad.Flagrp170 on B16 tumor cells

What problem does this paper attempt to address?

Supplementary Figure S4 from A Multifunctional Chimeric Chaperone Serves As a Novel Immune Modulator Inducing Therapeutic Antitumor Immunity

Xiaofei Yu,Chunqing Guo,Huanfa Yi,Jie Qian,Paul B. Fisher,John R. Subjeck,Xiang-Yang Wang

DOI: https://doi.org/10.1158/0008-5472.22399031

2023-01-01

Abstract:Supplementary Figure S4 PDF file - 86K, Ad.Flagrp170 therapy augments a potent immune response against B16 melanoma
Supplementary Figure S6 from A Multifunctional Chimeric Chaperone Serves As a Novel Immune Modulator Inducing Therapeutic Antitumor Immunity

Xiaofei Yu,Chunqing Guo,Huanfa Yi,Jie Qian,Paul B. Fisher,John R. Subjeck,Xiang-Yang Wang

DOI: https://doi.org/10.1158/0008-5472.22399025

2023-01-01

Abstract:Supplementary Figure S6 PDF file - 53K, Ad.Flagrp170 therapy of TRAMP-C2 prostate tumor and CT-26 tumor induces a strong tumor- or antigen-reactive immune response
Supplementary Figure S1 from A Multifunctional Chimeric Chaperone Serves As a Novel Immune Modulator Inducing Therapeutic Antitumor Immunity

Xiaofei Yu,Chunqing Guo,Huanfa Yi,Jie Qian,Paul B. Fisher,John R. Subjeck,Xiang-Yang Wang

DOI: https://doi.org/10.1158/0008-5472.22399040

2023-01-01

Abstract:Supplementary Figure S1 PDF file - 85K, Flagrp170 stimulates enhanced activation of DCs
Supplementary Figure S2 from A Multifunctional Chimeric Chaperone Serves As a Novel Immune Modulator Inducing Therapeutic Antitumor Immunity

Xiaofei Yu,Chunqing Guo,Huanfa Yi,Jie Qian,Paul B. Fisher,John R. Subjeck,Xiang-Yang Wang

DOI: https://doi.org/10.1158/0008-5472.22399037

2023-01-01

Abstract:Supplementary Figure S2 PDF file - 71K,TLR5 expression has little effect on activation of NF-B and MAPKs in bone marrowderived DCs following adenovirus-mediated delivery of Flagrp170
Supplementary Figure S5 from A Multifunctional Chimeric Chaperone Serves As a Novel Immune Modulator Inducing Therapeutic Antitumor Immunity

Xiaofei Yu,Chunqing Guo,Huanfa Yi,Jie Qian,Paul B. Fisher,John R. Subjeck,Xiang-Yang Wang

DOI: https://doi.org/10.1158/0008-5472.22399028

2023-01-01

Abstract:Supplementary Figure S5 PDF file - 145K, A . Recruitment of CD8+CD11c+ and CD11b+F4/80+ cells to the tumor sites following Ad.Flagrp170 therapy. B16 tumor-bearing mice were treated with indicated adenoviruses, and cell infiltration was analyzed using FACS by gating on tumor infiltrating leukocytes. B. IL-12p70 production in tumor-infiltrating myeloid cells was measured using intracellular cytokine staining assays. CD11c+ cells are not the major source of IL-12 (n=3, representative of 3 independent experiments). C. Flow cytometry analysis of splenic CD11c+ cells in DTx (8 ng/kg)-treated chimera mice reconstituted with BM from DTRtg mice
Supplementary Figure Legends and Supplementary Figures 1 Through 4 from A Novel Therapeutic Strategy to Rescue the Immune Effector Function of Proteolytically Inactivated Cancer Therapeutic Antibodies

Xiaohui Fan,Randall J. Brezski,Hui Deng,Pooja Dhupkar,Yun Q. Shi,Anneliese Gonzalez,Songlin Zhang,Michael A. Rycyzyn,William R. Strohl,Robert E. Jordan,Ningyan Zhang,Zhiqiang An

DOI: https://doi.org/10.1158/1535-7163.22501711

2023-01-01

Abstract:Figure S1: IdeS expression in BT474 breast cancer cells Figure S2: Detection of MMPs in cancer cell lysates and culture supernatant Figure S3: scIgG-T was not in the SKBR-3 cell culture medium Figure S4: Detection of immune cells infiltration in mice by flow cytometry.
A Multifunctional Chimeric Chaperone Serves As a Novel Immune Modulator Inducing Therapeutic Antitumor Immunity.

Xiaofei Yu,Chunqing Guo,Huanfa Yi,Jie Qian,Paul B. Fisher,John R. Subjeck,Xiang-Yang Wang

DOI: https://doi.org/10.1158/0008-5472.can-12-1740

2023-01-01

Abstract:Abstract Converting the immunosuppressive tumor environment into one that is favorable to the induction of antitumor immunity is indispensable for effective cancer immunotherapy. Here, we strategically incorporate a pathogen (i.e., flagellin)-derived, NF-κB–stimulating “danger” signal into the large stress protein or chaperone Grp170 (HYOU1/ORP150) that was previously shown to facilitate antigen crosspresentation. This engineered chimeric molecule (i.e., Flagrp170) is capable of transporting tumor antigens and concurrently inducing functional activation of dendritic cells (DC). Intratumoral administration of adenoviruses expressing Flagrp170 induces a superior antitumor response against B16 melanoma and its distant lung metastasis compared with unmodified Grp170 and flagellin. The enhanced tumor destruction is accompanied with significantly increased tumor infiltration by CD8+ cells as well as elevation of IFN-γ and interleukin (IL)-12 levels in the tumor sites. In situ Ad.Flagrp170 therapy provokes systemic activation of CTLs that recognize several antigens naturally expressing in melanoma (e.g., gp100/PMEL and TRP2/DCT). The mechanistic studies using CD11c-DTR transgenic mice and Batf3-deficient mice reveal that CD8α+ DCs are required for the improved T-cell crosspriming. Antibody neutralization assays show that IL-12 and IFN-γ are essential for the Flagrp170-elicited antitumor response, which also involves CD8+ T cells and natural killer cells. The therapeutic efficacy of Flagrp170 and its immunostimulating activity are also confirmed in mouse prostate cancer and colon carcinoma. Together, targeting the tumor microenvironment with this chimeric chaperone is highly effective in mobilizing or restoring antitumor immunity, supporting the potential therapeutic use of this novel immunomodulator in the treatment of metastatic diseases. Cancer Res; 73(7); 2093–103. ©2013 AACR.
In situ immune modulation therapy with a novel chimeric chaperone generates a potent antitumor response

Xiaofei Yu,Chunqing Guo,Huanfa Yi,Paul Fisher,John Subjeck,Xiang-Yang Wang

DOI: https://doi.org/10.4049/jimmunol.190.supp.140.7

2013-01-01

Abstract:Abstract The immunosuppressive tumor microenvironment (TME) represents a major hurdle for cancer immunotherapy. In the present study, we evaluate the feasibility of conditioning the immune environment in the tumor sites for induction of effective antitumor immunity using a novel immune modulator Flagrp170. This chaperone-based immune modulating agent is created by integrating a pathogen (i.e., flagellin)-derived ‘danger’ signal into Grp170, the largest chaperone resident in the endoplasmic reticulum. This chimeric chaperone molecule is highly efficient in inducing functional activation of dendritic cells via engaging the NF-κB and MAPK signaling pathways, and concurrently facilitating cross-presentation of tumor antigen. Intratumoral delivery of adenoviruses encoding Flagrp170 provokes a strong tumor-specific cytotoxic T lymphocyte response, leading to profound inhibition of tumor growth and metastasis. In situ Flagrp170 therapy preferentially drives the Th1 polarization of the TME, as evidenced by marked elevation of IL-12 and IFN-γ as well as increased tumor infiltration by CD8+ cells. Antibody depletion and blocking assays reveal that CD8+ cells and IFN-γ are essential for enhanced antitumor activity of Flagrp170. Our data demonstrate that this modified chaperone represents a promising immune modulating agent that may be utilized to potentially reverse immunosuppression in the TME and improve immunotherapeutic response to metastatic malignancies.
Supplementary Figure 4 from Augmentation of Immune Checkpoint Cancer Immunotherapy with IL18

Zhiliang Ma,Wen Li,Shinichi Yoshiya,Yong Xu,Masaki Hara,Yosif El‐Darawish,Tzvetanka Markova,Kyosuke Yamanishi,Hiromichi Yamanishi,Hideaki Tahara,Yoshimasa Tanaka,Haruki Okamura

DOI: https://doi.org/10.1158/1078-0432.22459815.v1

2023-01-01

Abstract:Cytotoxic activity exhibited by PECs from pre-implanted mice receiving immune checkpoint blockade and/or IL-18
Supplementary Figure 2 from Stat3 Inhibition Augments the Immunogenicity of B-cell Lymphoma Cells, Leading to Effective Antitumor Immunity

Fengdong Cheng,Hongwei Wang,Pedro Horna,Zi Wang,Bijal Shah,Eva Sahakian,Karrune V. Woan,Alejandro Villagra,Javier Pinilla-Ibarz,Said Sebti,Mitchell Smith,Jianguo Tao,Eduardo M. Sotomayor

DOI: https://doi.org/10.1158/0008-5472.22391792.v1

2023-01-01

Abstract:PDF file - 426K, Percent of T-cells
Supplementary Figure 1 from Stat3 Inhibition Augments the Immunogenicity of B-cell Lymphoma Cells, Leading to Effective Antitumor Immunity

Fengdong Cheng,Hongwei Wang,Pedro Horna,Zi Wang,Bijal Shah,Eva Sahakian,Karrune V. Woan,Alejandro Villagra,Javier Pinilla-Ibarz,Said Sebti,Mitchell Smith,Jianguo Tao,Eduardo M. Sotomayor

DOI: https://doi.org/10.1158/0008-5472.22391795.v1

2023-01-01

Abstract:PDF file - 111K, Viability and proliferation
Supplementary Figures from Dual Mechanisms of Novel CD73-Targeted Antibody and Antibody–Drug Conjugate in Inhibiting Lung Tumor Growth and Promoting Antitumor Immune-Effector Function

Rui Jin,Liang Liu,Yun Xing,Tao Meng,Li Ma,Jinpeng Pei,Ying Cong,Xuesai Zhang,Zhiqiang Ren,Xin Wang,Jingkang Shen,Ker Yu

DOI: https://doi.org/10.1158/1535-7163.22519333

2023-01-01

Abstract:Supplementary Figures and Tables
Supplementary Figure 2 from <i>In Situ</i> Vaccination with <i>CD204</i> Gene-Silenced Dendritic Cell, not Unmodified Dendritic Cell, Enhances Radiation Therapy of Prostate Cancer

Chunqing Guo,Huanfa Yi,Xiaofei Yu,Daming Zuo,Jie Qian,Gary Yang,Barbara A. Foster,John R. Subjeck,Xiaolei Sun,Ross B. Mikkelsen,Paul B. Fisher,Xiang-Yang Wang

DOI: https://doi.org/10.1158/1535-7163.22497105.v1

2023-01-01

Abstract:PDF file, 1232K, SRA/CD204-targeted radio-immunotherapy enhances cytolytic activity of effector T cells.
Supplementary Methods, Figures 1-15 from SM-164: A Novel, Bivalent Smac Mimetic That Induces Apoptosis and Tumor Regression by Concurrent Removal of the Blockade of Ciap-1/2 and XIAP

Jianfeng Lu,Longchuan Bai,Haiying Sun,Zaneta Nikolovska-Coleska,Donna McEachern,Su Qiu,Rebecca S. Miller,Han Yi,Sanjeev Shangary,Yi Sun,Jennifer L. Meagher,Jeanne A. Stuckey,Shaomeng Wang

DOI: https://doi.org/10.1158/0008-5472.22375851

2023-01-01

Abstract:Supplementary Methods, Figures 1-15 from SM-164: A Novel, Bivalent Smac Mimetic That Induces Apoptosis and Tumor Regression by Concurrent Removal of the Blockade of cIAP-1/2 and XIAP
Supplementary Figure 3 from Functional Characterization of an scFv-Fc Antibody that Immunotherapeutically Targets the Common Cancer Cell Surface Proteoglycan CSPG4

Xinhui Wang,Akihiro Katayama,Yangyang Wang,Ling Yu,Elvira Favoino,Koichi Sakakura,Alessandra Favole,Takahiro Tsuchikawa,Susan Silver,Simon C. Watkins,Toshiro Kageshita,Soldano Ferrone

DOI: https://doi.org/10.1158/0008-5472.22386500.v1

2023-01-01

Abstract:PDF file - 332K
Supplementary Figure S1 from Preclinical Pharmacokinetics, Tolerability, and Pharmacodynamics of Metuzumab, a Novel CD147 Human–Mouse Chimeric and Glycoengineered Antibody

Zheng Zhang,Yang Zhang,Qian Sun,Fei Feng,Muren Huhe,Li Mi,Zhinan Chen

DOI: https://doi.org/10.1158/1535-7163.22501722

2023-01-01

Abstract:Supplementary Figure S1. Images of anti-tumor efficacy of Metuzumab in SCID mice bearing A549 (left) and NCI-H520 (right) human lung cancer cell line xenografts.
Supplementary Figure 2 from Functional Characterization of an scFv-Fc Antibody that Immunotherapeutically Targets the Common Cancer Cell Surface Proteoglycan CSPG4

Xinhui Wang,Akihiro Katayama,Yangyang Wang,Ling Yu,Elvira Favoino,Koichi Sakakura,Alessandra Favole,Takahiro Tsuchikawa,Susan Silver,Simon C. Watkins,Toshiro Kageshita,Soldano Ferrone

DOI: https://doi.org/10.1158/0008-5472.22386506

2023-01-01

Abstract:PDF file - 263K
Supplementary Figure 8 from Multifunctional Bispecific Nanovesicles Targeting SLAMF7 Trigger Potent Antitumor Immunity

Manman Zhu,Yongjian Wu,Tianchuan Zhu,Jian Chen,Zhenxing Chen,Hanxi Ding,Siyi Tan,Jianzhong He,Qi Zeng,Xi Huang

DOI: https://doi.org/10.1158/2326-6066.26422580.v1

2024-01-01

Abstract:Supplementary Figure 8
Supplementary Data from XCL1/Glypican-3 Fusion Gene Immunization Generates Potent Antitumor Cellular Immunity and Enhances Anti–PD-1 Efficacy

Kun Chen,Zhiyuan Wu,Hong Zhao,Yanmei Wang,Yutong Ge,Dongmei Wang,Zhengjiang Li,Changming An,Yuying Liu,Feifei Wang,Xinyu Bi,Hongying Wang,Jianqiang Cai,Chunhong Ma,Chunfeng Qu

DOI: https://doi.org/10.1158/2326-6066.22543440

2023-01-01

Abstract:Supplementary Tables 1-2 and Supplementary Figures 1-8
Supplementary Figure S3 from Combination Therapy Targeting Ribosome Biogenesis and Mrna Translation Synergistically Extends Survival in MYC-Driven Lymphoma

Jennifer R. Devlin,Katherine M. Hannan,Nadine Hein,Carleen Cullinane,Eric Kusnadi,Pui Yee Ng,Amee J. George,Jake Shortt,Megan J. Bywater,Gretchen Poortinga,Elaine Sanij,Jian Kang,Denis Drygin,Sean O'Brien,Ricky W. Johnstone,Grant A. McArthur,Ross D. Hannan,Richard B. Pearson

DOI: https://doi.org/10.1158/2159-8290.22530953

2023-01-01

Abstract:This figure shows supplementary data pertinent to Figure 3 including protein and cell immunofluorescence analysis data.

Supplementary Figure S3 from A Multifunctional Chimeric Chaperone Serves As a Novel Immune Modulator Inducing Therapeutic Antitumor Immunity

Supplementary Figure S4 from A Multifunctional Chimeric Chaperone Serves As a Novel Immune Modulator Inducing Therapeutic Antitumor Immunity

Supplementary Figure S6 from A Multifunctional Chimeric Chaperone Serves As a Novel Immune Modulator Inducing Therapeutic Antitumor Immunity

Supplementary Figure S1 from A Multifunctional Chimeric Chaperone Serves As a Novel Immune Modulator Inducing Therapeutic Antitumor Immunity

Supplementary Figure S2 from A Multifunctional Chimeric Chaperone Serves As a Novel Immune Modulator Inducing Therapeutic Antitumor Immunity

Supplementary Figure S5 from A Multifunctional Chimeric Chaperone Serves As a Novel Immune Modulator Inducing Therapeutic Antitumor Immunity

Supplementary Figure Legends and Supplementary Figures 1 Through 4 from A Novel Therapeutic Strategy to Rescue the Immune Effector Function of Proteolytically Inactivated Cancer Therapeutic Antibodies

A Multifunctional Chimeric Chaperone Serves As a Novel Immune Modulator Inducing Therapeutic Antitumor Immunity.

In situ immune modulation therapy with a novel chimeric chaperone generates a potent antitumor response

Supplementary Figure 4 from Augmentation of Immune Checkpoint Cancer Immunotherapy with IL18

Supplementary Figure 2 from Stat3 Inhibition Augments the Immunogenicity of B-cell Lymphoma Cells, Leading to Effective Antitumor Immunity

Supplementary Figure 1 from Stat3 Inhibition Augments the Immunogenicity of B-cell Lymphoma Cells, Leading to Effective Antitumor Immunity

Supplementary Figures from Dual Mechanisms of Novel CD73-Targeted Antibody and Antibody–Drug Conjugate in Inhibiting Lung Tumor Growth and Promoting Antitumor Immune-Effector Function

Supplementary Figure 2 from <i>In Situ</i> Vaccination with <i>CD204</i> Gene-Silenced Dendritic Cell, not Unmodified Dendritic Cell, Enhances Radiation Therapy of Prostate Cancer

Supplementary Methods, Figures 1-15 from SM-164: A Novel, Bivalent Smac Mimetic That Induces Apoptosis and Tumor Regression by Concurrent Removal of the Blockade of Ciap-1/2 and XIAP

Supplementary Figure 3 from Functional Characterization of an scFv-Fc Antibody that Immunotherapeutically Targets the Common Cancer Cell Surface Proteoglycan CSPG4

Supplementary Figure S1 from Preclinical Pharmacokinetics, Tolerability, and Pharmacodynamics of Metuzumab, a Novel CD147 Human–Mouse Chimeric and Glycoengineered Antibody

Supplementary Figure 2 from Functional Characterization of an scFv-Fc Antibody that Immunotherapeutically Targets the Common Cancer Cell Surface Proteoglycan CSPG4

Supplementary Figure 8 from Multifunctional Bispecific Nanovesicles Targeting SLAMF7 Trigger Potent Antitumor Immunity

Supplementary Data from XCL1/Glypican-3 Fusion Gene Immunization Generates Potent Antitumor Cellular Immunity and Enhances Anti–PD-1 Efficacy

Supplementary Figure S3 from Combination Therapy Targeting Ribosome Biogenesis and Mrna Translation Synergistically Extends Survival in MYC-Driven Lymphoma